review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Mahlon DeLong | Q15374218 |
William M. McDonald | Q67228349 | ||
P2093 | author name string | Irene H Richard | |
P2860 | cites work | A rating scale for depression | Q24564540 |
An Inventory for Measuring Depression | Q26778503 | ||
Basal ganglia output and cognition: evidence from anatomical, behavioral, and clinical studies | Q28140388 | ||
Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant | Q28324024 | ||
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease | Q28369292 | ||
A New Depression Scale Designed to be Sensitive to Change | Q29614720 | ||
Fluoxetine in Parkinson's disease | Q67226561 | ||
In vivo stereological assessment of caudate volume in man: effect of normal aging | Q68592055 | ||
Depression in Parkinson's disease | Q68694013 | ||
Fluoxetine and extrapyramidal side effects | Q69414840 | ||
Parkinson's disease, depression, and the on-off phenomenon | Q69940431 | ||
Parkinson's disease camouflaging early signs of hypothyroidism | Q70518079 | ||
Does fluoxetine aggravate Parkinson's disease? A pilot prospective study | Q72000199 | ||
Parkinson's disease and depression: the relationship to disability and personality | Q72090835 | ||
Dopamine and depression | Q72222122 | ||
Parkinsonism exacerbated by paroxetine | Q72884150 | ||
Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes | Q73776786 | ||
Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression | Q74446178 | ||
Minor and subsyndromal depression: functional disability worth treating | Q77873245 | ||
IMIPRAMINE IN TREATMENT OF PARKINSONISM: A DOUBLE-BLIND PLACEBO STUDY | Q78407425 | ||
Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography | Q30495686 | ||
Transcranial magnetic stimulation: applications in neuropsychiatry | Q30572921 | ||
Magnetic resonance in patients with affective illness | Q30997803 | ||
Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory | Q33630514 | ||
Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? | Q33660662 | ||
Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? | Q33733822 | ||
Depression and anxiety in Parkinson's disease: possible effect of genetic variation in the serotonin transporter | Q33873790 | ||
Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease | Q33917650 | ||
Functional changes of the basal ganglia circuitry in Parkinson's disease. | Q33924857 | ||
Non-dopaminergic drug treatment of Parkinson's disease | Q34240947 | ||
Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease | Q34305931 | ||
Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity | Q34646047 | ||
Applications of transcranial magnetic stimulation in movement disorders | Q35000091 | ||
Depression and Parkinson's disease: a review | Q35313173 | ||
Homocysteine, folate, methylation, and monoamine metabolism in depression | Q35458595 | ||
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study | Q35467921 | ||
Effect of age at onset on frequency of depression in Parkinson's disease | Q36864189 | ||
Cognitive impairments and depression in Parkinson's disease: a follow up study | Q36938802 | ||
A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease | Q36961731 | ||
The etiology of depression in Parkinson's disease patients | Q37556320 | ||
Coexisting dementia and depression in Parkinson's disease | Q38209726 | ||
Neuropsychological and psychiatric sequelae of pallidotomy for PD: clinical trial findings | Q38435548 | ||
Neuropsychological impairment in Parkinson's disease with and without depression | Q38462009 | ||
Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease | Q40621648 | ||
The importance of subsyndromal depression in older primary care patients: prevalence and associated functional disability | Q40809937 | ||
Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects | Q41197355 | ||
Anxiety and Parkinson's disease | Q41442784 | ||
Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study | Q41607274 | ||
Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study | Q41787776 | ||
Increase of Parkinson disability after fluoxetine medication | Q42289259 | ||
Connections of the subthalamic nucleus with ventral striatopallidal parts of the basal ganglia in the rat. | Q42484629 | ||
The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics. | Q42509207 | ||
SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. | Q42655854 | ||
Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. | Q42691933 | ||
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. | Q43520287 | ||
The correlation of depression with functional activity in Parkinson's disease | Q43538074 | ||
Antecedent clinical features associated with dementia in Parkinson's disease | Q43577797 | ||
Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. | Q43590767 | ||
In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease | Q43670960 | ||
Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease | Q43974492 | ||
Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease | Q43977645 | ||
Homocysteine in neuropsychiatric disorders of the elderly | Q44131619 | ||
Depressive symptoms as relative and attributable risk factors for first-onset major depression | Q44274354 | ||
??? | Q64862715 | ||
The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa | Q45711592 | ||
Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population | Q46068701 | ||
ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptides | Q47994670 | ||
Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. | Q48448624 | ||
Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats | Q48458364 | ||
Depression and Parkinson's disease: a new look at an old problem | Q48497066 | ||
Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson's disease: an open study | Q48552742 | ||
The neuropathologic basis of different clinical subgroups of Parkinson's disease | Q48633612 | ||
The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease: a discriminant analytic approach. | Q48637566 | ||
On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study | Q48661239 | ||
Altered serotonin metabolism in depressed patients with parkinson's disease | Q48680548 | ||
Risk factors for depression in Parkinson disease | Q48719363 | ||
Clinical, motor, and biological correlates of depressive disorders after focal subcortical lesions | Q48738450 | ||
The motor performance test series in Parkinson's disease is influenced by depression | Q48786674 | ||
Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease | Q48939047 | ||
Depression and medical illness in late life: report of a symposium | Q50107221 | ||
An estimate of the incidence of depression in idiopathic Parkinson's disease. | Q50543153 | ||
Effectiveness of ECT in patients with parkinsonism. | Q50885058 | ||
Depression and disability in Parkinson's disease. | Q51003628 | ||
Factors impacting on quality of life in Parkinson's disease: results from an international survey. | Q51055467 | ||
Relationship between mood and motor fluctuations in Parkinson's disease. | Q51070527 | ||
Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: Preliminary findings | Q51124819 | ||
Mood changes and "on-off" phenomena in Parkinson's disease. | Q51170704 | ||
Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. | Q51973773 | ||
Maintenance ECT in Parkinson's disease. | Q51975587 | ||
Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. | Q52002538 | ||
The occurrence of depression in Parkinson's disease. A community-based study. | Q52009711 | ||
Comparison of cognitive changes in patients with Alzheimer's and Parkinson's disease. | Q52033168 | ||
Depression, intellectual impairment, and Parkinson disease. | Q52101557 | ||
A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. | Q52864240 | ||
The quality of life in Parkinson's disease. | Q53524833 | ||
Sertraline for the treatment of depression in Parkinson's disease. | Q53964557 | ||
S-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. | Q55034448 | ||
Bupropion in Parkinson's disease. | Q55062563 | ||
Tolerability of paroxetine in Parkinson's disease: A prospective study | Q57203470 | ||
Transient Acute Depression Induced by High-Frequency Deep-Brain Stimulation | Q60490586 | ||
Paroxetine in Parkinson's disease: effects on motor and depressive symptoms | Q64765320 | ||
Depression in Parkinson's disease | Q64785206 | ||
Thyroid function in Parkinson disease | Q64787317 | ||
Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA | Q64791376 | ||
Keeping depression at bay helps patients with Parkinson disease | Q64854681 | ||
Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series | Q64866414 | ||
Elevated plasma levels of homocysteine in Parkinson's disease | Q64867918 | ||
Depression in classic versus akinetic-rigid Parkinson's disease | Q64922801 | ||
Cognitive functions in major depression and Parkinson disease | Q64972083 | ||
Desipramine in treatment of Parkinson's disease. A placebo-controlled study | Q67215620 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Parkinson's disease | Q11085 |
P304 | page(s) | 363-75 | |
P577 | publication date | 2003-08-01 | |
P1433 | published in | Biological Psychiatry | Q4914961 |
P1476 | title | Prevalence, etiology, and treatment of depression in Parkinson's disease | |
P478 | volume | 54 |
Q64806377 | Q64806377 |
Q64864842 | Q64864842 |
Q36307871 | A matter of motion or an emotional matter? Management of depression in Parkinson's disease |
Q37275088 | Alexithymia and apathy in Parkinson's disease: neurocognitive correlates |
Q37605604 | Altered directional connectivity between emotion network and motor network in Parkinson's disease with depression |
Q36255233 | Alternatives to levodopa in the initial treatment of early Parkinson's disease |
Q48359779 | Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats |
Q48250330 | Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain |
Q27318295 | Apathy, Novelty Processing, and the P3 Potential in Parkinson's Disease |
Q35189606 | Assessing depression and factors possibly associated with depression during the course of Parkinson's disease. |
Q37210088 | Assessment of depression in three medically ill, elderly populations: Alzheimer's disease, Parkinson's disease, and stroke |
Q36969544 | Associated and predictive factors of depressive symptoms in patients with Parkinson's disease. |
Q40765887 | Associations of pain and depression with marital status in patients diagnosed with Parkinson's disease. |
Q36140767 | Bilateral subthalamic nucleus stimulation for Parkinson's disease: a systematic review of the clinical literature |
Q82029017 | Chapter 50 Pain in Parkinson's disease |
Q43165318 | Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons |
Q35946064 | Cognition in mania and depression: psychological models and clinical implications |
Q92968669 | Comorbid Depression and Psychosis in Parkinson's Disease: A Report of 62,783 Hospitalizations in the United States |
Q37973611 | Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease. |
Q47968188 | Cortical thinning in drug-naive Parkinson's disease patients with depression. |
Q90116092 | Curcumin restores rotenone induced depressive-like symptoms in animal model of neurotoxicity: assessment by social interaction test and sucrose preference test |
Q48405825 | Deep brain stimulation for the treatment of Parkinson's disease. |
Q36446704 | Depression and coronary heart disease |
Q48452383 | Depression and intelligence in patients with Parkinson's disease and deep-brain stimulation |
Q42646021 | Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). |
Q43835412 | Depression in Parkinson's disease. Assessment and treatment |
Q50194256 | Depression in patients with Parkinson's disease and the associated features |
Q37225955 | Depression in the medically ill: diagnostic and therapeutic implications |
Q34578187 | Depression rating scales in Parkinson's disease: critique and recommendations |
Q47759633 | Depressive Symptoms are Frequent in Atypical Parkinsonian Disorders. |
Q36738506 | Depressive symptoms in Parkinson's disease and in non-neurological medical illnesses. |
Q24815683 | Developmental pesticide models of the Parkinson disease phenotype |
Q47642861 | Diagnostic Validity and Factor Analysis of Montgomery-Asberg Depression Rating Scale in Parkinson Disease Population |
Q40189130 | Discordance Between Physician Assessment and Patient-Reported Depressive Symptoms in Parkinson Disease |
Q37685695 | Dopamine receptor agonists and depression in Parkinson's disease |
Q64235467 | Effectiveness of imaging genetics analysis to explain degree of depression in Parkinson's disease |
Q34102890 | Effects of depression and social support on comprehension and recall of informed consent information among Parkinson disease patients and their caregivers |
Q36744761 | Emotional state affects gait initiation in individuals with Parkinson's disease |
Q47950883 | Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes |
Q33634151 | Frequency specific brain networks in Parkinson's disease and comorbid depression |
Q46800578 | Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions |
Q37156009 | Genome-wide linkage screen in familial Parkinson disease identifies loci on chromosomes 3 and 18 |
Q40719044 | Hematopoietic cytokines as therapeutic players in early stages Parkinson's disease. |
Q43037703 | Illness comorbidity as a biomarker? |
Q45776139 | Impact of Depression on Hospitalization and Related Outcomes for Parkinson's Disease Patients: A Nationwide Inpatient Sample-Based Retrospective Study |
Q41469238 | Impact of ethnicity on mood disorders in Parkinson's disease |
Q36696078 | Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil |
Q45124937 | Influence of Mild Cognitive Impairment, Depression, and Anxiety on the Quality of Life of Patients with Parkinson Disease |
Q43622007 | Influence of continuous infusion of interleukin-1beta on depression-related processes in mice: corticosterone, circulating cytokines, brain monoamines, and cytokine mRNA expression |
Q37315808 | Introduction: chronic medical conditions and depression--the view from primary care |
Q92591063 | Leucine-rich repeat kinase-2 (LRRK2) modulates paraquat-induced inflammatory sickness and stress phenotype |
Q24629770 | MAO-inhibitors in Parkinson's Disease |
Q48483209 | MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions. |
Q34302897 | Major depressive disorder in Parkinson's disease: a cross-sectional study from Sri Lanka |
Q28066691 | Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases |
Q73739199 | Mood disorders and medical illness: a major public health problem |
Q33303267 | Motor deficits and altered striatal gene expression in aphakia (ak) mice |
Q36615980 | Movement disorders: neurodevelopment and neurobehavioural expression |
Q38176606 | Neural and behavioral substrates of subtypes of Parkinson's disease |
Q37071589 | Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease |
Q36525764 | Non-motor aspects of Parkinson's disease. |
Q47826150 | Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. |
Q94371699 | Parkinson's disease |
Q28264391 | Parkinson's disease |
Q36567378 | Paroxetine for somatic pain associated with physical illness: a review |
Q52311656 | Patterns and Predictors of Depression Treatment among Older Adults with Parkinson's Disease and Depression in Ambulatory Care Settings in the United States. |
Q41838690 | Phenomenology and management of cognitive and behavioral disorders in Parkinson's disease. Rise and logic of dementia in Parkinson's disease |
Q46589346 | Practical experience on improving activities of daily living competence in Parkinson's patients treated with ropinirole. Results of a applied study |
Q41110293 | Prevalence of depression in Parkinson's disease in a Lebanese tertiary clinic. |
Q50890389 | Prevalence of depression in a 12-month consecutive sample of patients with ALS. |
Q35043972 | Prevalence of incompletely penetrant Huntington's disease alleles among individuals with major depressive disorder |
Q26766021 | Psychosocial Modulators of Motor Learning in Parkinson's Disease |
Q36006174 | Qualitative Characteristics of Depression in Parkinson's Patients and Controls |
Q45352049 | Quality of life in relation to mood, coping strategies, and dyskinesia in Parkinson's disease |
Q48401125 | Resting-state fMRI study on drug-naive patients with Parkinson's disease and with depression. |
Q35893872 | Retracted: Influences of Chronic Mild Stress Exposure on Motor, Non-Motor Impairments and Neurochemical Variables in Specific Brain Areas of MPTP/Probenecid Induced Neurotoxicity in Mice |
Q48128398 | Rotenone selectively kills serotonergic neurons through a microtubule-dependent mechanism |
Q33715050 | Screening for Depressive Disorder in Elderly Patients with Chronic Physical Diseases Using the Patient Health Questionnaire-9. |
Q36679249 | Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. |
Q46252066 | Sertraline in the treatment of depressive disorders in patients with Parkinson's disease |
Q64926088 | Simultaneous Detection of Dopamine and Serotonin-A Comparative Experimental and Theoretical Study of Neurotransmitter Interactions. |
Q60053953 | Sleep Quality, Depression, and Quality of Life After Bilateral Anodal Transcranial Direct Current Stimulation in Patients with Parkinson's Disease |
Q80351905 | Sleep disorders in Parkinson's disease |
Q30480822 | Startle reflex hyporeactivity in Parkinson's disease: an emotion-specific or arousal-modulated deficit? |
Q48431005 | Stress exacerbates experimental Parkinson's disease |
Q35713356 | Stress, depression and Parkinson's disease |
Q37312897 | Subthreshold depression in Parkinson's disease |
Q48507111 | The diagnosis and treatment of depression in Parkinson's disease |
Q36074454 | The impact of depressive symptoms in early Parkinson disease |
Q48301186 | The impact of sleep and mood disorders on quality of life in Parkinson's disease patients |
Q37129850 | The patients' perspective: Results of a survey assessing knowledge about and attitudes toward depression in PD |
Q36871133 | The psychomotor theory of human mind. |
Q35101458 | The role of cognitive-behavioural therapy for patients with depression in Parkinson's disease |
Q47322917 | The role of ghrelin, neuropeptide Y and leptin peptides in weight gain after deep brain stimulation for Parkinson's disease |
Q47915497 | The role of social support in anxiety and depression among Parkinson's disease patients |
Q36826802 | Treatment consideration and manifest complexity in comorbid neuropsychiatric disorders |
Q34272602 | Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease |
Q37158450 | Triple reuptake inhibitors as potential next-generation antidepressants: a new hope? |
Q43763804 | Untreated depressive symptoms among cognitively-intact, community dwelling Filipino patients with Parkinson disease |
Q33767361 | Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease |
Q50117645 | Voluntary Physical Exercise Improves Subsequent Motor and Cognitive Impairments in a Rat Model of Parkinson's Disease |
Q33856140 | What are the causes of late-life depression? |
Q48091560 | White matter microstructure changes in the thalamus in Parkinson disease with depression: A diffusion tensor MR imaging study |
Q53427550 | Zanthoxylum alatum abrogates lipopolysaccharide-induced depression-like behaviours in mice by modulating neuroinflammation and monoamine neurotransmitters in the hippocampus. |